ReviewCancer management and research2026
Advances in Phase III Clinical Trials and Future Challenges of Targeted Therapy in Advanced Ovarian Cancer.
Review in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced ovarian cancer (OC) is characterized by an insidious onset, a high recurrence rate, and complex mechanisms of drug resistance, and has long been associated with poor prognosis, representing one of the leading causes of cancer-related death among women worldwide. In recent years, rapid advances in molecular biology and translational medicine have markedly transformed the therapeutic landscape of advanced ovarian cancer. Targeted therapies, including bevacizumab-based anti-angiogenic therapy, PARP inhibitors, and antibody-drug conjugates, act on key oncogenic pathways involved in tumor angiogenesis, DNA damage repair, and tumor-specific antigens, and have significantly prolonged PFS, with OS benefits observed in selected patient populations. This review systematically summarizes the major mechanisms underlying targeted therapy in advanced ovarian cancer and highlights the key evidence and clinical value of these three major classes of targeted agents in phase III clinical trials. By integrating mechanistic insights with phase III clinical evidence, this review further proposes that future research should focus on the evolution of therapeutic resistance, long-term safety management, standardized biomarker testing, and the optimization of combination and sequential treatment strategies. With the continued refinement of predictive biomarkers, improvement of multi-target combination approaches, and development of novel targeted agents, further gains in survival and quality of life are anticipated for patients with advanced ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.